UK Rapid Test Consortium
The UK Rapid Test Consortium (UK-RTC) is a United Kingdom industry consortium created to produce a lateral flow rapid test for COVID-19. Rapid tests are a form of COVID-19 testing technology that was originally developed from significant investment by the United Kingdom government to develop new forms of COVID-19 testing that provided advantages over existing forms such as PCR. Its members include Abingdon Health, BBI Solutions, CIGA Healthcare, Omega Diagnostics, and Oxford University.
In 2020, the consortium developed the AbC-19 rapid test to meet UK government requirements for a rapid testing solution. The government ordered 1 million of the UK-RTC's rapid tests in October 2020.
CIGA Healthcare will be responsible for assembly and distribution, and has also been awarded distribution to the US after recent FDA approval.
- "rapidmicrobiology UK Begin At-Home COVID-19 Antibody Testing Programme". www.rapidmicrobiology.com. Retrieved 2020-11-13.
- "Industry responds to call to arms to build British diagnostics industry at scale". GOV.UK. Retrieved 2020-11-13.
- "Government invests in UK-developed antibody tests from UK Rapid Test Consortium". GOV.UK. Retrieved 2020-11-13.
- "Yorkshire developed Covid-19 test approved for use in North America".
Media files used on this page
This illustration, created at the Centers for Disease Control and Prevention (CDC), reveals ultrastructural morphology exhibited by coronaviruses. Note the spikes that adorn the outer surface of the virus, which impart the look of a corona surrounding the virion, when viewed electron microscopically. A novel coronavirus, named Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), was identified as the cause of an outbreak of respiratory illness first detected in Wuhan, China in 2019. The illness caused by this virus has been named coronavirus disease 2019 (COVID-19).